Ipsc Articles & Analysis
16 articles found
Induced pluripotent stem cells (iPSCs) have revolutionized the field of regenerative medicine and cellular biology. They are derived from somatic cells that have been genetically reprogrammed back into an embryonic-like pluripotent state. This transformation enables them to differentiate into any cell type, offering significant potential for disease modeling, drug discovery, and therapeutic ...
Alfa Cytology has announced pancreatic cancer vaccine development services to improve the efficacy and safety of related vaccines. Alfa Cytology, a biotech company composed of scientists, bioinformatics, and oncologists, has recently announced its pancreatic cancer vaccine development services to provide further strategies for cancer therapy research. Compared to other solid tumors, ...
The process of iPSC differentiation to neurons and neuronal cells is of special importance for neurobiology and related disorders, considering the dearth of clinically relevant in vitro models available for research, drug screening and development, as well as the lack of therapy to reverse neuronal damage. Benefits and advantages of iPSC differentiation to neural stem cells (NSC), neurons and ...
A key concern in iPSC-based therapeutic applications is the safety of the cell products to be transplanted into patients. Although the in vivo teratoma formation assay is an effective method to directly assess the tumorigenicity of undifferentiated cells, it is also costly and time-consuming. Now, Creative Bioarray presents a quick and cost-effective assay to detect residual undifferentiated ...
Pluripotent stem cells — cells with the ability to differentiate into nearly any cell type in the body, constituting a significant potential for regenerative medicine. Among these, induced Pluripotent Stem Cells (iPSCs), in particular, have garnered substantial interest from the scientific community due to their ability to be produced from adult cells, eliminating the ethical quandaries ...
For this month’s reagent round up, I would like to share a comparative data set showcasing our MatriClone matrix. MatriClone is an exciting opportunity for customers looking to accelerate their cell therapy workflows and deliver new treatments to market. For those who are not familiar with the matrix, it is comprised of truncated recombinant Laminin-511 protein and is designed to support ...
Previously, it was thought that glial cells, which support neuronal activity, metabolize most of the glucose in the brain. However, by using induced pluripotent stem cells, the researchers found that neurons were able to take up glucose and process it into smaller metabolites. In mice, normal function of neurons depends on glycolysis. The findings could help develop new treatments for ...
The clinical presentation of COVID-19-related illness ranges from asymptomatic to mild respiratory symptoms resembling influenza infection to acute symptoms including pneumonia requiring hospitalization and admission to the intensive care unit. COVID-19 starts in the upper airways and lungs, but in severe cases can also affect the heart, blood vessels, brain, liver, kidneys, and intestines. ...
Induced pluripotent stem cells (iPSCs) can be generated from a wide range of fully differentiated cells and, under optimal conditions, can potentially be driven to differentiate into virtually any fate. Induced stem-like cells not only provide an alternative to embryonic stem cells but more importantly represent a powerful tool for drug development and disease modeling. Methods to induce ...
Cardiovascular safety liabilities caused 52.3 % of 44 marketed data from 1980 to 2011, and cardiovascular disease remains the leading cause of death globally, yet only 8.7% of cardiovascular drugs successfully pass clinical trials. These statistics demonstrate the need to address a patient’s specific genetic make-up and phenotype by adopting a personalized treatment methodology for ...
Many cell and gene therapy solutions have shown considerable promise as a source of possible treatments for a wide range of chronic disorders. However, these sophisticated therapies introduce additional barriers such as the requirements for ultra-low and cryogenic storage, which affect numerous steps of the biomedical solutions’ life cycles, from their development to their administration. ...
We had the chance to interview Teisha Rowland, Ph.D., Principal Scientist at Umoja Biopharma during the ISSCR in San Francisco about the Umoja/TreeFrog partnership. Leading iPSC engineering at Umoja, she comes back on the vision of Umoja, its RACR™ technology and her interest in TreeFrog’s C-Stem™ platform for the development of iPSC-derived allogeneic products in ...
Technology Networks interviews Dr. Mark Kotter, CEO of bit.bio. The interview digs deep into how bit.bio’s next generation cellular reprogramming technology, opti-ox™, is enabling scientists in research and drug discovery to overcome the shared challenges presented by human muscle models. Mark explains how pioneering work conducted in the 1980’s sparked the development of ...
Bybit.bio
This is the third module in a four part series titled “Zero to One on the basic science behind cultivated meat”. You can click on these links to access: Course Overview, Module 1 (Cell Culture Basics), Module 2 (Cell Sources), Module 4 (Process monitoring). Learning objectives By the end of this module, you should understand: Basal culture medium composition and sources; ...
There is a growing need to address the high failure rate of drug candidates as they progress through clinical trials. Altis Biosystems aims to bring its technological advances to the forefront, enabling the drug development process to more effectively translate results from preclinical experiments to late-stage clinical trials. Breaking the Conformity of Inadequate Testing Platforms The ...
Publication Summary: Recent advances in the directed differentiation of human pluripotent stem cells to kidney organoids advances the prospect of drug screening, disease modelling, and even restoration of renal function using patient-derived stem cell lines. Here, we demonstrate the successful adaptation of our directed differentiation protocol to the NovoGen Bioprinter® MMX technology to ...